GLP-1 Pipeline Tracker (2026)

Where every late-stage anti-obesity drug actually stands — retatrutide and MariTide, CagriSema and survodutide, pemvidutide, petrelintide, mazdutide, ecnoglutide, and bimagrumab with semaglutide. Each one carries its NCT ID, its primary completion date, its sponsor, and whatever topline result has actually been checked.

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

About this tracker

Most of what is below is still in late-stage development. When we re-checked in September 2026, one molecule was FDA-approved — Foundayo (orforglipron), approved April 1, 2026 — and one was under FDA review: Novo Nordisk filed CagriSema in December 2025 and expects a US decision in the fourth quarter of 2026. Lilly plans to submit retatrutide to the FDA in the first quarter of 2027. Four programs draw most of the attention: retatrutide (Eli Lilly triple agonist, TRIUMPH phase 3), MariTide (Amgen monthly GIPR/GLP-1 conjugate, MARITIME phase 3), CagriSema (Novo Nordisk cagrilintide+semaglutide, REDEFINE phase 3), and survodutide (Boehringer Ingelheim / Zealand, SYNCHRONIZE phase 3). Every NCT ID here was checked against ClinicalTrials.gov itself, and every PMID looked up on PubMed rather than recalled. Trial readout dates and FDA approval timelines change frequently — verify against the current ClinicalTrials.gov record before making any clinical or investment decision.

Safety notice: Investigational drugs are not FDA-approved for general use. Nothing here is medical advice. Not one of these drugs can be bought outside a clinical trial (Foundayo, which is FDA-approved for chronic weight management). Compounded retatrutide is not eligible under FDA 503A or 503B; this article does not endorse any compounded product. See our retatrutide regulatory framework article for access timeline context. You cannot read one drug's weight-loss percentage against another's: the trials differ in how long they ran, what they compared against, what dose they used, and population differ.

Recent readouts

Completed — Nov 14, 2025

TRIUMPH-4 (Retatrutide)

Lilly (Dec 11, 2025): “weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.”

Obesity + knee OA. NCT05931367.

ClinicalTrials.gov →

Topline — Dec 20, 2024

REDEFINE-1 (CagriSema)

Novo Nordisk: “22.7% superior weight loss after 68 weeks” and “40.4% of patients reached ≥25% weight loss.”

Obesity without T2D. NCT05567796.

ClinicalTrials.gov →

Completed — Dec 2025

SYNCHRONIZE-1 (Survodutide)

Peer-reviewed in NEJM (online June 7, 2026; PMID 42253238). By the paper's primary treatment-regimen estimand, mean weight change at week 76 was −12.2% on 3.6 mg and −13.0% on 6.0 mg vs −5.4% on placebo. The 16.6% vs 3.2% in the sponsors' releases is the efficacy estimand.

Obesity without T2D. NCT06066515.

ClinicalTrials.gov →PubMed →

Published — NEJM 2025

MariTide Phase 2 (NEJM 2025)

Jastreboff et al. (PMID 40549887): −12.3% to −16.2% vs −2.5% placebo at Week 52. Monthly dosing (Q4W). Phase 3 MARITIME-1/2 ongoing.

N=592. Obesity without T2D.

PubMed →

NMPA-Approved — June 2025 (China)

Mazdutide (GLORY-1)

Approved in China for chronic weight management on June 27, 2025 — mainly on GLORY-1 data, per Innovent — and for glycemic control on September 19, 2025. A 9 mg application built on GLORY-2 was accepted for review in November 2025 and is still pending. Lilly and Innovent have not announced a US filing, and a Chinese approval is no guide to an FDA decision.

GCG/GLP-1 dual agonist. Innovent / Lilly (China).

NMPA-Approved — March 2026 (China)

Ecnoglutide (SLIMMER)

China's NMPA cleared Sciwind's XW003 for chronic weight management in March 2026. The SLIMMER trial finished in June 2024. Sciwind has not announced a US filing, and a Chinese approval is no guide to an FDA decision.

Weekly GLP-1 RA. NCT05813795.

Full pipeline tracker table

NCT IDs checked on ClinicalTrials.gov; PMIDs looked up on PubMed. Trial-to-trial weight-loss percentages are not directly comparable — no two rows below share a duration, a comparator, a dose and a population.

Drug	Sponsor	Mechanism	Indication	Phase	Trial / NCT	Primary Completion	Status
RetatrutideLY3437943	Eli Lilly	GIP / GLP-1 / glucagon triple agonist	Obesity (without T2D)	Phase 3	TRIUMPH-1 NCT05929066	April 6, 2026	Completed
RetatrutideLY3437943	Eli Lilly	GIP / GLP-1 / glucagon triple agonist	T2D + obesity	Phase 3	TRIUMPH-2 NCT05929079	June 16, 2026	Completed
RetatrutideLY3437943	Eli Lilly	GIP / GLP-1 / glucagon triple agonist	Severe obesity (BMI ≥35) + established CVD	Phase 3	TRIUMPH-3 NCT05882045	April 16, 2026	Completed
RetatrutideLY3437943	Eli Lilly	GIP / GLP-1 / glucagon triple agonist	Obesity + knee osteoarthritis	Phase 3	TRIUMPH-4 NCT05931367	November 14, 2025	Completed
RetatrutideLY3437943	Eli Lilly	GIP / GLP-1 / glucagon triple agonist	BMI ≥27 + ASCVD or CKD (CV and kidney outcomes)	Phase 3	TRIUMPH-Outcomes NCT06383390	February 2029	Active, not recruiting
Maridebart cafraglutideMariTide	Amgen	GIPR antagonist + GLP-1 agonist mAb-peptide (monthly Q4W)	Obesity (without T2D)	Phase 3	MARITIME-1 NCT06858839	January 2027	Active, not recruiting
Maridebart cafraglutideMariTide	Amgen	GIPR antagonist + GLP-1 agonist mAb-peptide (monthly Q4W)	T2D + obesity	Phase 3	MARITIME-2 NCT06858878	January 2027	Active, not recruiting
CagriSemacagrilintide 2.4 mg + semaglutide 2.4 mg	Novo Nordisk	Amylin analog + GLP-1 agonist fixed-dose combo	Obesity (without T2D)	Phase 3	REDEFINE-1 NCT05567796	October 2024	Active, not recruiting
CagriSemacagrilintide 2.4 mg + semaglutide 2.4 mg	Novo Nordisk	Amylin analog + GLP-1 agonist fixed-dose combo	T2D + obesity	Phase 3	REDEFINE-2 NCT05394519	January 2025	Completed
CagriSemacagrilintide 2.4 mg + semaglutide 2.4 mg	Novo Nordisk	Amylin analog + GLP-1 agonist fixed-dose combo	Established CVD (event-driven CVOT)	Phase 3	REDEFINE-3 NCT05669755	September 2027	Active, not recruiting
SurvodutideBI 456906	Boehringer Ingelheim / Zealand Pharma	GLP-1 / glucagon dual agonist	Obesity (without T2D)	Phase 3	SYNCHRONIZE-1 NCT06066515	December 2025	Completed
Orforglipron / FoundayoOral non-peptide GLP-1 RA (FDA-approved Apr 1, 2026)	Eli Lilly	Non-peptide oral GLP-1 receptor agonist	OSA + obesity (one expansion; T2D separately submitted to FDA)	Phase 3 expansion	ATTAIN-OSA NCT06649045	November 2026	Approved (expansion)
EcnoglutideXW003	Sciwind Biosciences	Weekly GLP-1 receptor agonist	Chronic weight management (China; no US filing announced)	Phase 3	SLIMMER NCT05813795	June 2024	Completed
PemvidutideALT-801	Altimmune	GLP-1 / glucagon dual agonist	MASH (FDA Breakthrough Therapy + Fast Track; Phase 3 PERFORMA started Jul 30, 2026)	Phase 2b	IMPACT NCT05989711	November 25, 2025	Completed
Bimagrumab + SemaglutideBYM338 + semaglutide (via Versanis)	Eli Lilly (Versanis acquisition)	Activin type II receptor blocker + GLP-1 agonist	Obesity — fat mass reduction	Phase 2	BELIEVE NCT05616013	May 2024	Completed
MazdutideIBI362	Innovent / Eli Lilly (China license)	GCG / GLP-1 dual agonist	Chronic weight management (China; no US filing announced)	Phase 3	GLORY-2 NCT06164873	June 2025 (stale registry estimate; JAMA: trial ran to Nov 2025)	Unknown (registry not updated)
PetrelintideZP8396	Zealand Pharma / Roche	Long-acting amylin analog	Obesity (dose-finding; Phase 3 planned H2 2026)	Phase 2	ZUPREME-1 NCT06662539	September 2025	Completed

Last verified: September 11, 2026. Trial statuses move often, so check the live ClinicalTrials.gov record before relying on any row.

Per-drug profiles

Retatrutide (LY3437943) — Eli Lilly

GIP / GLP-1 / Glucagon Triple AgonistPhase 3 (TRIUMPH)Not yet FDA-approved

Three receptors at once: GIP, GLP-1 and glucagon. It is the glucagon arm that is thought to push energy expenditure past what dual-agonism achieves. The phase 2 trial (Jastreboff et al., NEJM 2023, PMID 37366315) produced approximately 24.2% mean weight loss at 48 weeks at the highest dose.

TRIUMPH-4 (NCT05931367, completed Nov 14, 2025): Obesity + knee osteoarthritis. Lilly press release (Dec 11, 2025) reads: “Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial.”

TRIUMPH-1 (NCT05929066, completed; primary completion April 6, 2026): Obesity without T2D. Lilly press release (May 21, 2026; not peer-reviewed) reads: “In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks”. At week 80, by the efficacy estimand: −19.0% / −25.9% / −28.3% on 4 / 9 / 12 mg vs −2.2% on placebo. By the treatment-regimen estimand: −17.6% / −23.7% / −25.0% vs −3.9%.

TRIUMPH-2 (NCT05929079, completed; primary completion June 16, 2026): T2D + obesity. Lilly press release (July 23, 2026; not peer-reviewed) reads: “Participants taking retatrutide 4 mg, 9 mg, and 12 mg lost an average of 29.8 lbs (12.7%), 45.4 lbs (19.1%), and 49.6 lbs (20.8%), respectively, alongside A1C reductions of up to an average of 1.6%.” Week 80, efficacy estimand; placebo −4.0%.

TRIUMPH-3 (NCT05882045, completed; primary completion April 16, 2026): Severe obesity (BMI ≥35) with established cardiovascular disease. Same Lilly release (July 23, 2026; not peer-reviewed): −21.6% on 9 mg and −22.6% on 12 mg vs −3.2% on placebo at week 80, efficacy estimand. Its cardiovascular-event hazard ratios have confidence intervals that cross 1 (MACE-5: 0.82, 95% CI 0.55 to 1.22), so they do not show a cardiovascular benefit.

TRIUMPH-Outcomes (NCT06383390): BMI ≥27 + ASCVD or CKD; cardiovascular and kidney outcomes, event-driven; primary completion February 2029; active, not recruiting. An earlier version of this page labeled this trial “TRIUMPH-3”; TRIUMPH-3 is NCT05882045, above.

Note: As of Lilly's second-quarter 2026 report (August 5, 2026), retatrutide had not been submitted to the FDA. The same report lists it “with plans to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027” — a BLA, not an NDA. A planned submission is not an approval, and we cannot predict approval timing. We found no peer-reviewed TRIUMPH paper on PubMed as of September 11, 2026. Compounded retatrutide is not eligible under FDA 503A or 503B. See our retatrutide regulatory framework article for full context.

TRIUMPH-1 NCT →TRIUMPH-2 NCT →TRIUMPH-3 NCT →TRIUMPH-Outcomes NCT →TRIUMPH-4 NCT →Full evidence article →

Maridebart Cafraglutide (MariTide) — Amgen

GIPR Antagonist + GLP-1 Agonist (Monthly Q4W)Phase 3 (MARITIME)

MariTide is a monoclonal antibody-peptide conjugate enabling once-monthly (Q4W) subcutaneous dosing. Phase 2 published in NEJM 2025 (Jastreboff et al., PMID 40549887, NEJM 2025;393:843–857): −12.3% to −16.2% vs −2.5% placebo at Week 52. NOTE: some secondary sources cite “Nature Medicine Dec 2024” for MariTide — that is incorrect. The peer-reviewed publication is NEJM 2025.

Amgen press release (Nov 26, 2024) reads: “MariTide demonstrated up to ~20% average weight loss at week 52 without a weight loss plateau.”

MARITIME-1 (NCT06858839): Obesity without T2D; primary completion January 2027.

MARITIME-2 (NCT06858878): T2D + obesity; primary completion January 2027.

MARITIME-1 NCT →MARITIME-2 NCT →PMID 40549887 →

CagriSema — Novo Nordisk

Amylin + GLP-1 Fixed-Dose CombinationPhase 3 (REDEFINE)

CagriSema combines semaglutide 2.4 mg (GLP-1 agonist) with cagrilintide 2.4 mg (long-acting amylin analog). Cagrilintide monotherapy Phase 2 was published as Lau et al., Lancet 2021 (PMID 34798060).

REDEFINE-1 (NCT05567796): Obesity without T2D. Novo (Dec 20, 2024): “22.7% superior weight loss after 68 weeks”; “40.4% of patients reached ≥25% weight loss.”

REDEFINE-2 (NCT05394519, completed): T2D + obesity; announced superior weight loss (Novo press release, March 2025).

REDEFINE-3 (NCT05669755): Established CVD CVOT; event-driven; primary completion September 2027.

US filing: Novo Nordisk submitted a New Drug Application to the FDA on December 18, 2025, and its August 4, 2026 half-year report lists a US decision among its fourth-quarter 2026 milestones. Not approved: we found no CagriSema approval on Drugs@FDA as of September 11, 2026.

REDEFINE-1 NCT →Full CagriSema deep-dive →

Survodutide (BI 456906) — Boehringer Ingelheim / Zealand Pharma

GLP-1 / Glucagon Dual AgonistPhase 3 (SYNCHRONIZE)

Phase 2 published as le Roux et al., Lancet Diabetes & Endocrinology 2024 (PMID 38330987). Note: some secondary sources cite NEJM 2024 for survodutide — that is incorrect. The published Phase 2 is Lancet Diabetes & Endocrinology 2024.

SYNCHRONIZE-1 (NCT06066515) — obesity without T2D — completed December 2025 and is now peer-reviewed (le Roux et al., NEJM, online June 7, 2026; PMID 42253238). By the paper's primary treatment-regimen estimand, mean weight change at week 76 was −12.2% on 3.6 mg and −13.0% on 6.0 mg vs −5.4% on placebo. The larger figure in the sponsors' releases — up to 16.6% vs 3.2% — is the efficacy estimand, which estimates the effect had everyone stayed on treatment.

SYNCHRONIZE-MASLD is published in Nature Medicine (PMID 42252333). SYNCHRONIZE-2 (NCT06066528, T2D) completed in December 2025; Zealand says its results will be presented at EASD 2026, and no topline figures are public yet.

SYNCHRONIZE-1 NCT →PMID 38330987 →

Petrelintide (ZP8396) — Zealand Pharma / Roche

Long-Acting Amylin AnalogPhase 2 → Phase 3 Planned H2 2026

ZUPREME-1 (NCT06662539) completed September 2025. Zealand topline (March 2026): up to 10.7% mean body weight reduction at Week 42 vs 1.7% placebo. Zealand and Roche announced in April 2026 intent to advance to Phase 3 with planned initiation in H2 2026. ZUPREME-2 (NCT06926842, T2D + obesity) completed on August 13, 2026; Zealand expects its topline results in the second half of 2026.

ZUPREME-1 NCT →

Pemvidutide (ALT-801) — Altimmune

GLP-1 / Glucagon Dual AgonistPhase 3 MASH (PERFORMA) · FDA Breakthrough Therapy

MOMENTUM Phase 2 obesity topline (ADA 2024): −10.3% / −11.2% / −15.6% at 1.2/1.8/2.4 mg vs −2.2% placebo at Week 48. Press release / topline only; peer-reviewed PMID not yet verified. IMPACT Phase 2b MASH (NCT05989711) reached primary completion on November 25, 2025; its 24-week results are peer-reviewed in The Lancet (PMID 41237796).

Altimmune started the Phase 3 PERFORMA trial (NCT07795164, noncirrhotic MASH) on July 30, 2026, with 52-week data expected in 2029. Altimmune's second-quarter 2026 report (August 12, 2026) states: “Pemvidutide was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) based on 24-week data from the IMPACT Phase 2b trial”, on top of its Fast Track designation for MASH. The same report lists pemvidutide in development for MASH, alcohol use disorder and alcohol-associated liver disease; obesity is no longer on that list.

Bimagrumab + Semaglutide (BELIEVE) — Eli Lilly (Versanis)

Activin Type II Blocker + GLP-1 AgonistPhase 2 (Completed)

BELIEVE (NCT05616013) completed May 2024 and is peer-reviewed in Nature Medicine (Heymsfield et al., 2026; PMID 41772149). The primary endpoint, at week 48, was −17.8 kg on the high-dose combination (bimagrumab 30 mg/kg + semaglutide 2.4 mg) vs −14.2 kg on semaglutide 2.4 mg alone and −3.3 kg on placebo. The −22.1% figure is week 72, after a 24-week open-label extension: −24.2 kg (−22.1%) on the high-dose combination vs −16.5 kg (−15.7%) on semaglutide 2.4 mg. On the combination, fat mass accounted for 92.3% of weight lost at week 48 and 92.2% at week 72.

Hedge: Lilly has not committed to a Phase 3 for bimagrumab. The combination's path forward is uncertain based on Lilly public statements in 2025–2026.

Mazdutide (IBI362) — Innovent / Eli Lilly (China License)

GCG / GLP-1 Dual AgonistNMPA-Approved China Only

NMPA-approved in China for chronic weight management on June 27, 2025 — an approval Innovent says was mainly based on GLORY-1 (Ji et al., NEJM 2025, PMID 40421736) — and for glycemic control on September 19, 2025.

GLORY-2 (NCT06164873) tested a 9 mg dose and is published in JAMA (Gao et al., August 4, 2026; PMID 42251595): at week 60, mean weight change was −16.65% on mazdutide 9 mg vs −1.50% on placebo. The trial ran from December 2023 to November 2025; its ClinicalTrials.gov record was last updated in August 2024 and still shows status Unknown with an old June 2025 estimate. Innovent's GLORY-2-based application for the 9 mg dose was accepted for review in China on November 25, 2025 and is still pending.

Note: Lilly and Innovent have not announced a US filing. What China approves is no guide to what the FDA will do. The first US-based data, a Phase 2 trial, were published August 21, 2026 (Lancet Diabetes & Endocrinology, PMID 42628555).

Ecnoglutide (XW003) — Sciwind Biosciences

Weekly GLP-1 Receptor AgonistNMPA-Approved China Only

SLIMMER Phase 3 (NCT05813795) completed June 2024. NMPA-approved in China for chronic weight management March 2026.

Since May 2026, Sciwind has presented a week-20 interim from a 60-week, open-label Phase 2 against semaglutide in China (ADA 2026; an interim, not a final result) and has registered new Phase 3 trials in China in obstructive sleep apnea and knee osteoarthritis.

Note: Sciwind has not announced a US filing. What China approves is no guide to what the FDA will do.

Orforglipron / Foundayo — Eli Lilly (FDA-Approved + Expansion)

FDA-Approved 2026Oral Non-Peptide GLP-1 RA

Foundayo was FDA-approved in 2026 for chronic weight management — the first oral, non-peptide, small-molecule GLP-1 receptor agonist. Core approval based on ATTAIN-1 (Wharton et al., NEJM 2025, PMID 40960239).

Since the April 1, 2026 approval, Lilly has submitted Foundayo to the FDA for type 2 diabetes (announced June 8, 2026; confirmed as submitted in Lilly's August 5, 2026 second-quarter report). No new indication has been approved: as of September 11, 2026, the only post-approval action on Drugs@FDA is an August 4, 2026 labeling supplement. ATTAIN-OSA (NCT06649045, primary completion Nov 2026) is testing an obstructive sleep apnea indication, and a cardiovascular-outcomes Phase 3 is registered as NCT07241390.

How we verify this tracker

Every NCT ID verified by direct lookup on ClinicalTrials.gov before anything goes up. Trial name, sponsor, indication and primary completion date all come off the canonical record.
Every PMID confirmed by direct PubMed lookup. Secondary sources citing the wrong PMID are corrected and flagged (e.g., retatrutide PMID 37296075 is a triboelectric sensor paper; survodutide Phase 2 is Lancet Diab & Endocrinol 2024, not NEJM).
Manufacturer press releases get cited to the investor-relations URL and quoted word for word. A topline claim is never put into our own words.
Topline vs peer-reviewed are marked, never blurred. As of September 2026, pemvidutide's MOMENTUM and retatrutide's TRIUMPH-1, -2 and -3 exist only as press releases. Survodutide's SYNCHRONIZE-1 moved to peer review in June 2026 (NEJM), so we now quote the paper's estimand rather than the release's.

What we left out, and why

These were kept out: checking the primary sources turned up no NCT ID, no publication and no announcement from the manufacturer.

ATTAIN-MASH (orforglipron) — no orforglipron MASH Phase 3 found as of September 2026.
DREAM-1 / DREAM-2 (petrelintide) — the correct trial name is ZUPREME, not DREAM.

Found on our September 2026 re-check. Earlier versions of this page listed these as unconfirmed; each now has a registry record or a paper:

TRIUMPH-5 (retatrutide) — NCT06662383, retatrutide vs tirzepatide in obesity; active; primary completion estimated November 2026. Retatrutide in liver disease is in a Lilly Phase 3 master protocol, NCT07165028 (retatrutide, tirzepatide or placebo in MASLD; recruiting; estimated August 2030).
Orforglipron cardiovascular outcomes — NCT07241390 (major adverse cardiovascular events in people with ASCVD and/or CKD; recruiting; estimated August 2031). It carries no ATTAIN name.
Survodutide MASH Phase 3 (LIVERAGE) — NCT06632444 (noncirrhotic MASH; recruiting since October 2024) and NCT06632457 (LIVERAGE-Cirrhosis).
Mazdutide NEJM paper — GLORY-1, PMID 40421736 (published online May 25, 2025).

Primary sources cited

Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315
ClinicalTrials.gov NCT05929066 — TRIUMPH-1. clinicaltrials.gov →
ClinicalTrials.gov NCT05929079 — TRIUMPH-2. clinicaltrials.gov →
ClinicalTrials.gov NCT05931367 — TRIUMPH-4. clinicaltrials.gov →
Jastreboff AM et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. N Engl J Med. 2025;393:843–857. PMID 40549887
ClinicalTrials.gov NCT06858839 — MARITIME-1. clinicaltrials.gov →
Lau DCW et al. Efficacy and safety of once-weekly cagrilintide for weight management in adults with overweight and obesity. Lancet. 2021. PMID 34798060
ClinicalTrials.gov NCT05567796 — REDEFINE-1. clinicaltrials.gov →
le Roux CW et al. Efficacy and safety of survodutide for overweight and obesity. Lancet Diabetes Endocrinol. 2024. PMID 38330987
Wharton S et al. Orforglipron for the Treatment of Obesity. N Engl J Med. 2025. PMID 40960239
ClinicalTrials.gov NCT06066515 — SYNCHRONIZE-1. clinicaltrials.gov →
ClinicalTrials.gov NCT06662539 — ZUPREME-1. clinicaltrials.gov →
ClinicalTrials.gov NCT05882045 — TRIUMPH-3. clinicaltrials.gov →
ClinicalTrials.gov NCT06383390 — TRIUMPH-Outcomes. clinicaltrials.gov →
Eli Lilly and Company. “Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial.” Press release, May 21, 2026. PR Newswire →
Eli Lilly and Company. “Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C.” Press release, July 23, 2026. PR Newswire →
Eli Lilly and Company. “Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials.” Press release, June 8, 2026. PR Newswire →
Eli Lilly and Company. “Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress.” Press release, August 5, 2026. PR Newswire →
Novo Nordisk. “Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues for weight management.” Company announcement, December 18, 2025. novonordisk.com →
Novo Nordisk. Company announcement No 48/2026, half-year financial report, August 4, 2026. PDF →
le Roux CW et al. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026. PMID 42253238
Kaplan LM et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2026. PMID 42252333
Zealand Pharma. Press release on SYNCHRONIZE-1 results at ADA 2026 (efficacy-estimand figures), June 7, 2026. GlobeNewswire →
Zealand Pharma. Company announcement No. 39/2026, financial results for the first half of 2026, August 13, 2026 (petrelintide and survodutide timelines). Nasdaq Copenhagen →
Altimmune. Second-quarter 2026 financial results and business update (SEC Form 8-K, Exhibit 99.1), August 12, 2026. sec.gov →
Noureddin M et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study. Lancet. 2025. PMID 41237796
Heymsfield SB et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat Med. 2026. PMID 41772149
Ji L et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025. PMID 40421736
Gao L et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026. PMID 42251595
Hsia SH et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial. Lancet Diabetes Endocrinol. 2026. PMID 42628555
Innovent Biologics. “Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management.” Press release, June 27, 2025. PR Newswire →
Innovent Biologics. “Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population.” Press release, November 25, 2025. PR Newswire →

Common questions about the GLP-1 pipeline

The honest answer is that you cannot rank them, because the trials differ in length, comparator, dose and the people enrolled. What can be said: among peer-reviewed papers, the largest mean weight loss any Phase 2 or 3 has reported is still about 24% — retatrutide, week 48, in Phase 2 (Jastreboff, NEJM 2023). Lilly's press releases now report more, and none of it is peer-reviewed yet: 28.3% at 80 weeks on 12 mg in TRIUMPH-1 (efficacy estimand; 25.0% by the treatment-regimen estimand, May 2026), and 28.7% at 68 weeks on 12 mg in TRIUMPH-4, a trial in people with both obesity and knee osteoarthritis (efficacy estimand; 23.7% by the treatment-regimen estimand; an average of up to 71.2 lbs, December 2025). Setting those beside CagriSema's 22.7% at 68 weeks or MariTide's ~20% at 52 weeks would be comparing different populations under different designs, which is not a comparison at all.

Nobody can give a date yet, because it has not been submitted. Lilly has now announced a filing timeline: a Biologics License Application — a BLA, not an NDA — is to go to the FDA in the first quarter of 2027 (Lilly, July 23 and August 5, 2026). The three pivotal obesity trials have all read out: TRIUMPH-1 on May 21, 2026, and TRIUMPH-2 and TRIUMPH-3 on July 23, 2026, so far as press releases only, not peer-reviewed papers. An approval date depends on how the FDA's review goes after submission; any date offered before then is guesswork rather than a schedule.

How many receptors it switches on at once. Two makes it dual: tirzepatide (Zepbound, Mounjaro) hits GIP and GLP-1, survodutide hits GLP-1 and glucagon. Three makes it triple, which is what retatrutide does — GIP, GLP-1 and glucagon together. That third component is thought to raise energy expenditure through thermogenesis and lipolysis, and it is the usual explanation offered for retatrutide's numerically larger Phase 2 weight loss.

Not yet, but it is under FDA review. Novo Nordisk submitted a New Drug Application to the FDA on December 18, 2025, and its half-year report of August 4, 2026 lists a US decision among its fourth-quarter 2026 milestones. We found no CagriSema approval on Drugs@FDA as of September 11, 2026. Novo announced the REDEFINE-1 topline on December 20, 2024: 22.7% weight loss by week 68.

One of them, and only by prescription: Foundayo, orforglipron, approved in 2026. Everything else on this tracker exists for patients solely inside a clinical trial. Any seller offering an investigational pipeline drug outside a trial is selling an unapproved, unregulated product — and the FDA has issued warning letters for precisely that.

Because leaving them out would misrepresent where obesity-drug development actually stands globally. Both hold NMPA approval in China — mazdutide since June 2025, ecnoglutide since March 2026 — and neither sponsor has announced a US filing. We say so plainly rather than implying otherwise: Chinese approval tells you nothing about what the FDA will do.

Amgen's maridebart cafraglutide is not a peptide but a monoclonal antibody conjugated to one, working as a GIPR antagonist and a GLP-1 receptor agonist at the same time. The antibody scaffold is what matters practically: it stretches the half-life far enough for a subcutaneous injection every four weeks. Phase 2 recorded weight loss between −12.3% and −16.2% by week 52 (Jastreboff, NEJM 2025; PMID 40549887), and Amgen has reported up to around 20% average loss with no plateau appearing. If MARITIME Phase 3 holds up, dosing monthly instead of weekly is a serious adherence advantage.

Petrelintide, from Zealand and Roche, is a long-acting amylin analog given on its own. CagriSema is a fixed-dose combination pairing Novo's amylin analog cagrilintide with semaglutide. Both act on the amylin receptor, but they are different molecules from different companies and only one of them is a combination. ZUPREME-1 reported up to 10.7% weight loss at week 42 on monotherapy (Zealand topline, March 2026), with Phase 3 planned for the second half of 2026.

Retatrutide: complete evidence review →

Phase 2 data (PMID 37366315), all 4 TRIUMPH trials, TRIUMPH-4 topline, safety disclaimers.

Retatrutide approval & access timeline →

How an NDA would proceed, where 503A and 503B compounding sits, when it might realistically land, and who TRIUMPH is enrolling.

CagriSema REDEFINE trial deep-dive →

REDEFINE-1 and REDEFINE-2 gone through in full, with Novo's own announcements quoted and the result set against Wegovy.

Pipeline deep-dive: survodutide, MariTide, ecnoglutide →

The published evidence, how each one works, and where regulators are likely to land on the second tier.

GLP-1: every FDA-approved medication →

The hormone itself, what the receptor agonist class does with it, and all 11 approvals in one table.

FDA-approved weight-loss medications hub →

Master overview of every weight-loss drug the FDA has approved, the non-GLP-1 routes, and where the pipeline fits.